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Background: Abnormal Savda Munziq (ASMq), a traditional uyghur medicine, has shown anti-tumour properties
in vitro. This study attempts to confirm these effects in vivo and measure effects on the immune system.
Methods: Kunming mice transplanted with Sarcoma 180 cells were treated with ASMq (2–8 g/kg/day) by
intra-gastric administration compared to model and cyclophosphamide (20 mg/kg/day). After the 14th day post
tumour implant, thymus, liver, spleen and tumours were removed, weighed, and processed for histopathological
analysis. Blood samples were also taken for haematological and biochemical analyses including TNF-α , IL-1 β and
IL-2. Splenic lymphocyte function was measured with MTT; lymphocyte subpopulations were measured by flow
cytometry.
Results: ASMq treated animals had reduced tumour volume compared to model and increased concentrations of
TNF-α, IL-1β and IL-2 compared to untreated and to cyclophosphamide-treated animals. No histopathological
alterations were observed. The absence of viable S180 cells and the presence of necrotic cells and granulation
tissue were observed in tumour tissue of treated animals. The effect on T lymphocytes was unclear.
Conclusions: ASMq confirmed in vivo anti-tumour effects observed in vitro, which may be at least in part
mediated by increased immune activity.Background
Abnormal Savda Munziq (ASMq), a traditional Uyghur
medicinal herbal preparations from the Xinjiang region
of China has long been used in Traditional Uyghur
Medicine for the treatment of diseases such as digestive
cancer, diabetes, cardiovascular diseases or chronic
asthma [1]. Uyghur medicine considers Abnormal Savda
as a final pathologic product of ”combusted” body fluid
(e.g. Savda, Sapra, Khan, Balgham), heavier in weight
and thicker in texture, and easy to deposit against the
blood vessel thus causing dilatation, which ultimately
leads to chronic diseases such as tumour and cancer.
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reproduction in any medium, provided the orinitially on ASMq, before using other drugs such as
Abnormal Savda Mushil. This results in temperament
recovery and body fluid equilibrium. ASMq is widely
applied traditionally for the treatment of complex diseases
such as tumours.
Therefore it would seem appropriate to test the effects
of ASMq on the development of tumours in animals,
and verify biological data that might confirm effects and
orient towards a mechanism of action.
ASMq is a herbal formula that is described in the
Chinese Uyghur pharmacopoeia, composed of ten medi-
cinal herbs (Table 1) [2]. It is now produced commer-
cially (patent no. ZL02130082.8). For years, we have
been studying its effects, and so far these studies have
shown the capacity of ASMq to scavenge free radicals
and superoxide anions, [3] decrease biological markers
of oxidative stress in man, [4] protect mitochondria and
DNA [3] against OH- induced oxidative damage in al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Plants used in Uyghur herbal preparation Abnormal Savda Munziq (ASMq)
Latin name Family Part used Uyghur Name Chinese Name
Adiantum capillus-veneris L. Adiantaceae Whole plant Pirsiyavxan Tiexianjue
Alhagi pseudalhagi (Bieb.) Desv. Fabaceae Branch secretion Kök tantak Citang
Anchusa italica Retz. Boraginaceae Whole plant Gavziban Niushecao
Cordia dichotoma G.Forst. Boraginaceae Fruit Serbistan Pobumuguo
Euphorbia humifusa Willd. Euphorbia maculata L. Euphorbiaceae Whole plant Yalmankülak Dijincao
Foeniculum vulgare Mill. Apiaceae Fruit Arpabidiyan Xiaohuixiang
Glycyrrhiza uralensis Fisch. ex DC. Fabaceae Radix or rhizoma Qüqük buya Gancaogen
Glycyrrhiza inflata Batalin Fabaceae Radix or rhizoma
Glycyrrhiza glabra L. Fabaceae Radix or rhizoma
Lavandula angustifolia Mill. Lamiaceae Aerial parts Üstihuddus Xunyicao
Melissa officinalis L. Lamiaceae Whole plant Badrenjiboye hindi Mifenghua
Ziziphus jujuba Mill. Rhamnaceae Fruit Qilan Dazao
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tion and viability in vitro [2,5-7] and in vivo [2].
Because immunity plays a major role in protection
against cancer, and because ASMq might have an effect
also on the immune system, [8] we tested in this study
not only the effect of ASMq on tumour growth, but also
on markers of immunity such as TNF-α, interleukins IL-1β,
or IL-2, and the distribution of T-lymphocytes. The effects
of ASMq were compared to those of cyclophosphamide, a
standard comparator for S180 sarcoma cells.
Methods
Chemicals and reagents
Industrially prepared ASMq granules were provided by
Qikang Habo pharmaceutical Co., LTD, Xinjiang (batch
number106060). Cyclophosphamide was purchased from
HengRui pharmaceutical Co., LTD, JiangSu under SFDA
(State Food and Drug Administration) batch H32020857.
Mouse IL-1β ELISA, batch number: 56069011; Mouse IL-2
ELISA, batch number: 55708025; Mouse TNF-α ELISA,
batch number: 55674004, were purchased from Bender
MedSystems Co., Austria.
Animals and treatment
Kunming SPF mice (4 to 6 weeks old, body wt. 20 ± 2 g)
were provided by the Laboratory Animal Centre of the
Xinjiang Medical University. The mice were bred under
regular laboratory conditions, i.e., room temperature and
12/12-hour light-dark cycle with free access to standard
rodent chow and water. The Laboratory Animal Centre
of Medicine Animal Care and Use Committee of the
Medical University of Xinjiang at Urumqi approved all
experimental protocols. One hundred and twenty mice
were randomly divided into six groups of 20 animals:
– control group: no intervention, no treatment
(normal saline 20 μl/kg orally daily)– model group: injection of S180 cells, no treatment.
(normal saline 20 μl/kg orally daily)
– Low dose ASMq group: S180 cell injection, ASMq
2 g/kg orally daily
– Medium dose ASMq group: S180 cells injection,
ASMq 4 g/kg orally daily,
– High dose ASMq group: S180 cells injection, ASMq
8 g/kg orally daily,
– Cyclophosphamide (CY) group: S180 cells injection,
CY 20 mg/kg daily injection.
S180 cells were supplied by Laboratory Animal Centre
of Xinjiang military hospital.
Except for the control group, 0.2 mL (1 × 107 cells/ml)
of seven-day-old S180 ascites was transplanted into the
right axilla of the mouse. The whole operation was
finished in 30 min.
These treatments were started 24 h after tumour
inoculation and given once a day for 14 days.
Animal observation
Animals were observed and graded daily for activity, thin-
ness, appearance of skin and hair, appetite, irritability.
Tumour size was measured daily using a ruler, and
tumour size was plotted against time to measure tumour
growth velocity.
Assessment of tumour weight, thymus, liver and spleen
index
Twenty-four hours after the last treatment administra-
tion at day 14, the mice were sacrificed by cervical dis-
location. The thymus, spleen, liver and solid tumours
were removed and weighed. The anticancer activity
in vivo was expressed as an inhibitory rate calculated by
the formula: [(A–B)/A] × 100%, where, A and B were
the mean tumour weights of the model control and ex-
perimental groups, respectively. The spleen, liver and
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spleen, liver or thymus weight (g)/body weight (g).Histological Investigation
A portion of tumour, kidneys, thymus and liver were
fixed in 10% buffered formalin and the remaining tissue
was used for biochemical measurements. The tissues
were fixed in solutions of ethanol 70% for 3 h, ethanol
80% 2 h, ethanol 90% 1.5 h, ethanol 95% 2 h, and etha-
nol 100% 1 h. Tissues were embedded in paraffin and at
least four cross-sections were taken from each tumour,
kidneys, thymus and liver in 4–5 μm thickness and
stained with haematoxylin-eosin (H & E). Two changes
each of 2 min of xylene treatment were done and finally
tissue sections were mounted with DPX mountant. The
slides were observed for histopathological changes and
microphotographs were taken using an Olympus BX50
microscope system (Olympus, Japan).Splenic lymphocytes function
MTT test
The viability of the spleen lymphocyte was assessed by
MTT (3,4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium
bromide) assay, which is based on the reduction of
MTT by the mitochondrial dehydrogenase of intact cells
to a purple formazan product [5-7,9]. A suspension of
spleen cells was diluted to 1 × 107 cell/L; 100 μl of cell
suspension was seeded in 96-well plates (Coastar, Corning,
NY) with 100 μl RPMI-1640 containing 5 μg/mL ConA,
with three wells per sample. These were incubated for
12 h, 48, and 72 h in a 5% CO2 incubator at 37 °C. and
MTT assays were performed with thymus T lymphocyte.
100 μL of 0.5 mg/mL MTT in cell culture medium was
added to each well and incubated for 2 h. 100 μL of 10%
SDS, 0.01 M HCl solution was added to each well to
dissolve the formazan crystals formed. The plates were
covered with aluminium foil and kept in an incubator
for 12 h for dissolution of the formed formazan crys-
tals. Amount of formazan was determined measuring
the absorbance at 560 nm using a microplate reader
(DYNATECH MR 4000).Detection of lymphocyte subpopulations
Blood was immediately collected on heparin from the
orbital venous plexus after the 14th day treatment. CD3,
CD4, CD8 cells and CD4/CD8 ratio were assessed by flow
cytometers (FCM), using PE-CyTM5 Hamster Anti-
Mouse CD3e, Batch number 553065;PE Rat Anti-Mouse
CD4,Batch number 553048;FITC Rat Anti-Mouse CD8a,
Batch number 553030. These kits were purchased from
BD Biosciences and were used according to the BD Bios-
ciences reagent instructions.Evaluation of cytokines
Blood was immediately transferred into test tubes, and
kept at room temperature for 30 minutes, according to the
manufacturer’s protocol. The blood was then centrifuged
at 3000 rpm for 20 min, followed by serum assays for
tumour necrosis factor-α (TNF-α); interleukin-1β (IL-1β);
interleukin −2 (IL-2) using ELISA methods (see above).
Statistical procedures
Data are expressed as mean ± SD and were analysed
with SPSS 17.0 statistical software using the statistical
tests appropriate to the variables. A p value less than
0.05 was considered statistically significant.
Results
Mice daily activities
We observed mice behaviour, autonomic activities, in-
gestion, drinking, hairs, faeces and urine daily. There
was no secretion in eye, ear, nose and mouth. The 2 g/
kg ASMq group showed normal activity, general mental
state, clean fur; tumour growth incubation period (TT)
was 3 days, tumour growth velocity (TS) was slower
than in the model group. ASMq 4 g/kg group showed
normal activity, good mental state (better than 2 g/kg
group), clean fur (better than 2 g/kg group); TT was 3d,
TS was slower than 2 g/kg group. ASMq 8 g/kg group
showed normal activity, good mental state (better than
2 g/kg group and 4 g/kg group), clean fur (better than
2 g/kg group and 4 g/kg group); TT was 3d, and TS was
slower than 2 g/kg and 4 g/kg groups. CY group showed
normal activity, good mental state (better than 2 g/kg
group), clean fur (better than 2 g/kg group); TT was 4d,
and TS was the slowest. Model group showed decreased
activity, enlarged tumour, gloomy and unclean fur, and
listlessness; TT was 2d, and TS was the fastest.
Treatment effects on growth rate of transplanted S180
tumours and organ weight ratios
The anticancer effects of ASMq against S180 are shown
in Table 2 and Table 3. Treatment with cyclophosphamide
and ASMq resulted in markedly lower tumour weight.
Compared with controls, the tumour inhibition rates in
high, medium, low dose ASMq and cyclophosphamide-
treated mice were 49.1%, 64.3%, 43.4%, and 50.9%,
respectively. Low ASMq dosage group had significantly
higher tumour weight than the cyclophosphamide group
(p < 0.05). The medium-dose ASMq group had lowest
tumour weight. High ASMq dose group was not different
from cyclophosphamide.
The spleen index in all ASMq dose groups was signifi-
cantly higher than that of the model control group or
the CY treated mice (Table 3). There was no difference
in thymus weight index, but the liver index was higher
in low-dose ASMq mice than in model mice.
Table 2 Effect of treatment with Cyclophosphamide or abnormal Savda Munziq traditional Uyghur Medicine in Mice
Transplanted with S180 Tumour on total body and organ weights (mean ± SD)
Group Dosage (g/kg) Tumour weight (g) Thymus weight (g) Spleen weight (g) Liver weight (g) Body weight (g)
Control 0 0.00 ± 0.00 0.10 ± 0.01 0.09 ± 0.01 1.21 ± 0.05 30.40 ± 1.44
Model 0 0.60 ± 0.03 0.09 ± 0.02 0.12 ± 0.01 1.30 ± 0.07 32.57 ± 1.50
CY 0.02 0.29 ± 0.01* 0.07 ± 0.01 0.08 ± 0.01 1.15 ± 0.05 25.96 ± 1.32
ASMq low 2 0.34 ± 0.02*# 0.10 ± 0.01# 0.11 ± 0.01*# 1.35 ± 0.13*# 27.34 ± 1.26*#
ASMq medium 4 0.21 ± 0.18*# 0.09 ± 0.01*# 0.12 ± 0.02*# 1.35 ± 0.37 29.82 ± 2.24#
ASMq high 8 0.30 ± 0.53* 0.11 ± 0.14# 0.11 ± 0.11*# 1.23 ± 1.30 30.22 ± 1.93#
* different from the tumour control group, p 0.05;
# different from the CY group, #p 0.05;
CY: cyclophosphamide.
ASMq: abnormal Savda Munziq traditional Uyghur medicine.
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Effects of ASMq on IL-1β, IL-2, and TNF-α concentra-
tions are shown in Table 4. IL-1, IL-2 and TNF-α con-
centrations were lower in the model and CY groups
than in the control group. Animals treated with ASMq
2 g/kg, 4 g/kg, 8 g/kg had significantly higher TNF-α
concentration (p < 0.05) than controls but not IL-1β.
Compared with the model group, groups treated with
ASMq 2 g/kg, 4 g/kg, or 8 g/kg had significantly higher




+ and CD4/CD8 Ratio
CD3 and CD4
+ cells were lower in all treatment groups
than in the control group, CD3 were significantly lower
in the high ASMq dose and 2 g/kg ASMq groups than
in the untreated cancer model (p <0.05), a pattern also
reproduced for CD4 cells, though not significantly. Only
the high dosage group had significantly lower CD8
+
(p <0.05) (Table 5).
Pathological examination
In the untreated Model group, (Figure 1–1 to 1–4) S180
axillary tumours had large, irregular tumour cells, with
large nuclei and little cytoplasm. Tumour growth wasTable 3 Effect of treatment with Cyclophosphamide or abnor
Transplanted with S180 Tumour on organ weight indices (org
Group Dosage
(g/kg)




Control group 0 3.3 ± 0.5 3.1 ±
Model group 0 2.8 ± 0.9 3.6 ±
CY 0.02 2.6 ± 0.3 2.9 ±
ASMq low 2 3.6 ± 0.4# 4.0 ±
ASMq
medium
4 3.0 ± 0.7 4.2 ±
ASMq high 8 3.5 ± 0/7# 3.5 ±
* different from the tumour control group, *p<0.05;
# different from the CY group, #p<0.05.
CY: cyclophosphamide.
ASMq: abnormal Savda Munziq traditional Uyghur medicine.rapid and invasive, with poorly defined boundaries
between tumour and adipose tissues, In Figure 1–1 and
1–3, tumour tissue has invaded the muscle tissue. Although
there was little inflammatory infiltrate, the tumoural
necrotic areas were very pronounced.
Pathology results are shown in Figure 1.
In CY-treated animals (Figure 1–5, 1–6) islets of viable
polymorphic cells were surrounded by large areas of
ischemic necrosis, without sign of muscle fibre integrity.
No area with viable S180 cells was found, and some
areas of granulation tissue with formation of fibrous
tissues were found.
In the ASMq 4 g/kg group, ischemic necrosis is obvious
as well as phlogocyte infiltrates (Figure 1-11 to 1–12). The
ASMq 8 g/kg group also have obvious ischemic necrosis,
but less than the 4 g/kg group, and some other areas of
granulation tissue were observed (Figure 1-7 to 1–10). The
lower ASMq dosage group did not have signs or areas of
ischemic necrosis (Figure 1-13 to 1–14).
Splenic lymphocyte function
IN ASMq 2 g/kg, 4 g/kg, 8 g/kg groups splenic lymphocyte
proliferation was found, with an apparent dose-effect
relationship (Figure 2). At the different times (12 h,mal Savda Munziq traditional Uyghur Medicine in Mice
an weight in mg/bodyweight in g (x ± SD))




0.4 39.9 ± 2.8 0
0.4 40.1 ± 2.9 0
0.4 44.3 ± 3.0 50.88
0.5*# 49.4 ± 6.0*# 43.43
1.0*# 46.8 ± 13.2 64.26
0.3*# 40.8 ± 4.4 49.05
Table 4 Effect of treatment with Cyclophosphamide or abnormal Savda Munziq traditional Uyghur Medicine in Mice
Transplanted with S180 Tumour on IL-1β; IL-2; TNF-α in mice blood serum (mean ± SD)
Group Dosage (g/kg) IL-1β (pg/ml) IL-2 (pg/ml) TNF-α (pg/ml)
Control 0 511.42 ± 6.06*# 17.64 ± 0.99*# 16.64 ± 0.86*#
Model 0 405.79 ± 7.03 15.23 ± 0.86 14.75 ± 0.67
CY 0.02 447.58 ± 3.38 12.50 ± 0.92 13.53 ± 0.66
ASMq low 2 430.50 ± 4.63*# 17.15 ± 1.01*# 18.52 ± 0.80*#
ASMq medium 4 510.32 ± 3.60*# 23.55 ± 1.20*# 27.13 ± 0.87*#
ASMq high 8 420.03 ± 3.06*# 19.99 ± 1.27*# 21.30 ± 0.87*#
* different from the Model group, *p<0.05;
# different from the CY group, #p<0.05.
CY: cyclophosphamide.
ASMq: abnormal Savda Munziq traditional Uyghur medicine.
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associated with the most T cell proliferation.
Discussion
ASMq is widely used in traditional Uyghur medicine for
the treatment of complex diseases such as tumours. Pre-
vious studies have indeed found an antiproliferative ef-
fect of ASMq both in vitro on HepG2 and CACO cell
lines [6], and in vivo on methylhydrazine induced colon
cancer in rats [2]. It induces cytotoxicity and apoptosis
in vitro [5,7]. ASMq also appears to have immune-
modulating effects [8], which may also play a role in its
antiproliferative activity in vivo.
In the present study in S180 implanted mice, we con-
firm the antiproliferative effect of ASMq on the cancer
cells. There was an increased spleen index and lympho-
cyte proliferations. ASMq increased IL-1β, IL-2, TNF-α.
IL-1β and IL-2 are important lymphokines in vivo, and
can promote the proliferation of T cells, B cells, and
macrophages. In the anti-tumour immunity which is
predominantly cellular, T cells are the main immune
cells that can be cytotoxic directly, or indirectly through
the secretion of cytokines TNF-α, IFN-γ. Many of the
cytokines , such as IFN-γ or IL-2, can activate natural
Killer (NK) cells. NK cells in the absence of antibodies
can kill tumour cells in vivo. Activation of NK cellsTable 5 Effect of treatment with Cyclophosphamide or abnor
Transplanted with S180 Tumour, on the percentage of CD3
+, C
Group Dosage g/kg) CD3
+ T cell (%)
Control 0 60.0 ± 9.6
Model 0 54.6 ± 9.0
CY 0.02 53.4 ± 9.1
ASMq 2 49.0 ± 10.9*#
ASMq 4 58.2 ± 16.3
ASMq 8 45.1 ± 7.8*#
* different from the tumour control group, *p<0.05;
# different from the CY group, #p<0.05
CY: cyclophosphamide.
ASMq: abnormal Savda Munziq traditional Uyghur medicine.induces LAK cells and cytotoxic T cell maturation, etc.,
which in the anti-tumour immunity play an important
role in regulating lymphocyte proliferation. In addition,
activated NK cells can release cytokines TNF-α, IL-2,
etc., and stimulate macrophages.
Though these effects were for the most part statistically
significant, there was no clear dose-effect relationship,
with the middle dose of ASMq often more effective than
the higher dose. This may be related to increased cyto-
toxicity with the higher dose. The antitumoral effects of
ASMq were not very different from those of Cyclophos-
phamide on the S180 model, [10] though the effects on
cytokines were different with a greater effect of ASMq on
TNF-α and IL2, but not on T4 or T8 distribution.
According to the Chinese cancer research standard, a
Chinese herbal medicine is deemed effective when the
tumour inhibitory rate reaches 30% and above. ASMq eas-
ily surpassesd that threshold at all tested doses [11,12].
Beyond the antitumoral drugs derived from plants
(such as the vinca minor derivatives or the taxanes)
other traditional herbal medicines have shown antiproli-
ferative or cytotoxic effects on the same S180 mouse
model, alone [13] or combined with cyclophosphamide
[14], and on other animal tumour models [11]. Other
herbal extracts or traditional medicines have demon-
strated immune-modulating effects [15,16].mal Savda Munziq traditional Uyghur Medicine in Mice
D4
+, CD8
+ and CD4/CD8 ratio (m ± SD)
CD4
+ T cell (%) CD8
+ T cell (%) CD4/CD8 ratio
43.4 ± 10.1 22.9 ± 2.9 1.88 ± 0.30
37.7 ± 9.7 23.6 ± 5.8 1.62 ± 0.31
39.6 ± 7.6 22.0 ± 3.4 1.80 ± 0.25
28.3 ± 8.7 19.2 ± 5.8 1.52 ± 0.37
38.0 ± 9.0 21.1 ± 6.0 1.85 ± 0.38
28.6 ± 7.5 14.7 ± 3.0*# 1.85 ± 0.49
Figure 1 Histological sections of S180 myosarcoma in Kunming mice. Photomicrographs of five micron thick histological sections of S180
myosarcoma in Kunming mice: 1–4 untreated controls; 5,6: cyclophosphamide; 7–10: ASMq 8 g/kg; 11,12: ASMq 4 g/kg; 13, 14: ASMq 2 g/kg.
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In conclusion, the Uyghur medicine Abnormal Savda
Munziq, that is traditionally used to treat or prevent
cancer, showed in this study inhibition of injected S180Figure 2 Splenic lymphocyte proliferation. Variations in splenic lympho
controls injected with S180 cells; c: cyclophosphamide-treated tumour-beamyosarcoma in mice. ASMq appeared to activate
tumour-inhibiting or killing processes through the acti-
vation of lymphocytes and lymphokines or chemokines,
in addition to effects on cell division, DNA synthesiscyte proliferation: a: normal untreated controls; b: model untreated
ring mice; d, e, f: ASMq-treated tumour-bearing mice.
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models [5-7].
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